Literature DB >> 17619233

Cerebral ischemia, cell cycle elements and Cdk5.

Serge Timsit1, Bénédicte Menn.   

Abstract

Stroke is a devastating disorder that significantly contributes to death, disability, and healthcare costs. New therapeutic strategies have been recently focusing on the development of neuroprotective agents that could halt the underlying mechanisms of neuronal death leading to brain damage. Accumulating evidence implicates proteins that are normally involved in the regulation of the cell cycle to neuronal death following ischemic insult, suggesting that these proteins could be suitable targets for stroke therapy. In this brief review, we present in vitro and in vivo arguments linking cell cycle molecules, i.e., cyclins, mitotic cyclin-dependent kinases (Cdks), as well as non-mitotic Cdk5, to ischemic neuronal death. We also report the evaluation of the potential of Cdk inhibitors as neuroprotective strategy for ischemic injury.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17619233     DOI: 10.1002/biot.200700072

Source DB:  PubMed          Journal:  Biotechnol J        ISSN: 1860-6768            Impact factor:   4.677


  10 in total

1.  The pro-death role of Cited2 in stroke is regulated by E2F1/4 transcription factors.

Authors:  Tianwen Huang; Yasmilde Rodríguez González; Dianbo Qu; En Huang; Farzaneh Safarpour; Eugene Wang; Alvin Joselin; Doo Soon Im; Steve M Callaghan; Wassamon Boonying; Lisa Julian; Sally L Dunwoodie; Ruth S Slack; David S Park
Journal:  J Biol Chem       Date:  2019-04-09       Impact factor: 5.157

2.  Neuroprotection Induced by Transplanted CDK5 Knockdown Astrocytes in Global Cerebral Ischemic Rats.

Authors:  Andrea Becerra-Calixto; Gloria Patricia Cardona-Gómez
Journal:  Mol Neurobiol       Date:  2016-10-15       Impact factor: 5.590

3.  Role of CDK5/cyclin complexes in ischemia-induced death and survival of renal tubular cells.

Authors:  Tatiana Guevara; Mónica Sancho; Enrique Pérez-Payá; Mar Orzáez
Journal:  Cell Cycle       Date:  2014-03-25       Impact factor: 4.534

4.  Sustained (S)-roscovitine delivery promotes neuroprotection associated with functional recovery and decrease in brain edema in a randomized blind focal cerebral ischemia study.

Authors:  Estelle Rousselet; Anne Létondor; Bénédicte Menn; Yann Courbebaisse; Marie-Lise Quillé; Serge Timsit
Journal:  J Cereb Blood Flow Metab       Date:  2017-06-01       Impact factor: 6.200

5.  Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models.

Authors:  Bénédicte Menn; Stéphane Bach; Teri L Blevins; Mark Campbell; Laurent Meijer; Serge Timsit
Journal:  PLoS One       Date:  2010-08-12       Impact factor: 3.240

Review 6.  An unusual member of the Cdk family: Cdk5.

Authors:  Fatema A Dhariwala; Medha S Rajadhyaksha
Journal:  Cell Mol Neurobiol       Date:  2008-01-08       Impact factor: 5.046

7.  TFP5 peptide, derived from CDK5-activating cofactor p35, provides neuroprotection in early-stage of adult ischemic stroke.

Authors:  Ya-Bin Ji; Pei-Pei Zhuang; Zhong Ji; Yong-Ming Wu; Yong Gu; Xiao-Ya Gao; Su-Yue Pan; Ya-Fang Hu
Journal:  Sci Rep       Date:  2017-01-03       Impact factor: 4.379

Review 8.  Cellular and Molecular Mechanisms of R/S-Roscovitine and CDKs Related Inhibition under Both Focal and Global Cerebral Ischemia: A Focus on Neurovascular Unit and Immune Cells.

Authors:  Lucas Le Roy; Anne Letondor; Cloé Le Roux; Ahmed Amara; Serge Timsit
Journal:  Cells       Date:  2021-01-08       Impact factor: 6.600

Review 9.  Regulation of APC/C-Cdh1 and its function in neuronal survival.

Authors:  Angeles Almeida
Journal:  Mol Neurobiol       Date:  2012-07-27       Impact factor: 5.590

10.  CCL11 Differentially Affects Post-Stroke Brain Injury and Neuroregeneration in Mice Depending on Age.

Authors:  Simone Lieschke; Bozena Zechmeister; Matteo Haupt; Xuan Zheng; Fengyan Jin; Katharina Hein; Martin S Weber; Dirk M Hermann; Mathias Bähr; Ertugrul Kilic; Thorsten R Doeppner
Journal:  Cells       Date:  2019-12-26       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.